Table 2

Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated women
Outcome No. women-doses No. abnormalities Rate* Hazard ratio
Histological abnormalities
Any high grade Unvaccinated 15,192 138 6.4 1.0
Vaccinated (unadjusted) 0.76 (0.61 to 0.95)
Vaccinated (adjusted) 27,179 181 4.8 0.72 (0.58 to 0.91)
1 dose 2,568 27 9.7 1.47 (0.97 to 2.23)
2 doses 3,412 28 6.8 1.02 (0.68 to 1.53)
1 or 2 doses 5,980 55 8.0 1.20 (0.88 to 1.65)
Complete 21,199 126 4.1 0.61 (0.48 to 0.78)
CIN3/AIS Unvaccinated 15,192 61 2.8 1.0
Vaccinated (unadjusted) 0.68 (0.48 to 0.95)
Vaccinated (adjusted) 27,179 70 1.9 0.64 (0.45 to 0.90)
1 dose 2,568 12 4.3 1.40 (0.75 to 2.61)
2 doses 3,412 11 2.7 0.87 (0.46 to 1.67)
1 or 2 doses 5,980 23 3.3 1.09 (0.67 to 1.76)
Complete 21,199 47 1.5 0.53 (0.36 to 0.77)
CIN2 Unvaccinated 15,192 87 4.0 1.0
Vaccinated (unadjusted) 0.81 (0.61 to 1.06)
Vaccinated (adjusted) 27,179 122 3.2 0.78 (0.59 to 1.03)
1 dose 2,568 16 5.7 1.29 (0.76 to 2.20)
2 doses 3,412 18 4.4 0.99 (0.59 to 1.64)
1 or 2 doses 5,980 34 4.9 1.11 (0.75 to 1.66)
Complete 21,199 88 2.9 0.70 (0.52 to 0.94)
CIN1 Unvaccinated 15,192 163 7.5 1.0
Vaccinated (unadjusted) 0.86 (0.70 to 1.05)
Vaccinated (adjusted) 27,179 244 6.5 0.83 (0.68 to 1.02)
1 dose 2,568 20 7.2 0.89 (0.56 to 1.41)
2 doses 3,412 30 7.3 0.90 (0.61 to 1.33)
1 or 2 doses 5,980 50 7.2 0.90 (0.65 to 1.23)
Complete 21,199 194 6.3 0.82 (0.66 to 1.01)
Cytological abnormalities
High-grade cytology Unvaccinated 15,192 325 15.3 1.0
Vaccinated (unadjusted) 0.77 (0.67 to 0.89)
Vaccinated (adjusted) 27,179 442 11.9 0.75 (0.65 to 0.87)
1 dose 2,568 44 16.0 0.85 (0.62 to 1.17)
2 doses 3,412 67 16.5 0.95 (0.73 to 1.23)
1 or 2 doses 5,980 111 16.3 0.91 (0.73 to 1.13)
Complete 21199 331 10.9 0.71 (0.61 to 0.83)
Low-grade cytology Unvaccinated 15,192 2,306 125.8 1.0
Vaccinated (unadjusted) 0.77 (0.73 to 0.82)
Vaccinated (adjusted) 27,179 3,184 95.3 0.76 (0.72 to 0.80)
1 dose 2,568 250 101.9 0.67 (0.59 to 0.76)
2 doses 3,412 328 89.2 0.64 (0.57 to 0.72)
1 or 2 doses 5,980 578 94.3 0.66 (0.60 to 0.72)
Complete 21,199 2,606 95.5 0.79 (0.75 to 0.84)

*Rate per 1,000 person-years.

All high grade histology defined as CIN2, CIN3, AIS and mixed CIN3/AIS.

High-grade cytology defined as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell carcinoma, possible high-grade endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and adenocarcinoma.

Low-grade cytology defined as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain significance.

Unvaccinated refers to women screened who did not receive any dose of HPV vaccine; completely vaccinated refers to women who were clinically completely vaccinated with three doses of HPV vaccine.

Hazard ratios adjusted for remoteness, SES and age at first screening.

Gertig et al.

Gertig et al. BMC Medicine 2013 11:227   doi:10.1186/1741-7015-11-227

Open Data